Home BancShares vs Hilltop
HOMB and HTH side by side, both in commercial banks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HOMB and HTH compare
Home BancShares is the larger company, worth 2.9 times as much as Hilltop ($6.0B against $2.0B).
On earnings, Home BancShares is cheaper: it trades at 12.3× trailing earnings, against 14.9× for Hilltop.
Home BancShares grew revenue faster over the last twelve months (7.1% versus 0.21% for Hilltop).
Home BancShares keeps more of each dollar of sales as profit, with a net margin of 42.7% compared with 11.2% at Hilltop.
Both pay dividends: Home BancShares yields 2.2% and Hilltop 1.7%.
Home BancShares scores higher on the StockData Score (14 against 12 for Hilltop), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HOMB | HTH |
|---|---|---|
| Size and price | ||
| Market cap | $6.0B | $2.0B |
| Share price | $29.86 | $35.78 |
| Change, 1 year | 9.9% | 6.9% |
| Change, 5 years | 23.0% | 2.7% |
| Beta (5Y) | −0.08 | 0.21 |
| Employees | 2,543 | 3,500 |
| StockData Score | ||
| Total score | 14 (better) | 12 |
| Valuation score | 2 | 4 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 3 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 12.3× (better) | 14.9× |
| P/S | 5.3× | 1.6× (better) |
| P/B | 1.3× | 1.0× (better) |
| P/FCF | 13.9× (better) | 18.5× |
| PEG | 0.80 (better) | 0.82 |
| FCF yield | 7.2% (better) | 5.4% |
| Fair value | $29.87 | $37.26 |
| Margin of safety | 0.04% | 4.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.1% (better) | 0.21% |
| Revenue growth, 5Y average | 9.5% (better) | −9.5% |
| Net income growth (TTM) | 10.4% (better) | −11.7% |
| EPS growth (TTM) | 10.5% (better) | −4.4% |
| EPS growth, 5Y average | 13.1% (better) | −12.0% |
| Profitability | ||
| Net margin | 42.7% (better) | 11.2% |
| FCF margin | 38.3% (better) | 8.8% |
| Return on equity | 11.1% (better) | 6.6% |
| Financial health | ||
| Debt / equity | – | 0.39 |
| Altman Z-score | 0.36 (better) | 0.27 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 2.2% (better) | 1.7% |
| Payout ratio | 34.3% | 33.4% |
| Years of dividend growth | 12 (better) | 9 |
| Dividend growth, 5Y average | 8.7% | 14.9% (better) |
| Buyback yield | 1.3% | 8.6% (better) |
| Shareholder yield | 3.5% | 10.4% (better) |
| Ownership | ||
| Held by institutions | 76.9% | 56.3% |
| Held by insiders | 5.5% | 61.0% |
| Insider net buying, 12 months | $107K (better) | −$15.3M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.9% | 9.6% |
Go deeper
- HOMB stock overview
- HOMB income statement
- HOMB valuation and score
- HTH stock overview
- HTH income statement
- HTH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.